Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHELLE STEPHANIE ROSARIO

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1467847640
CMS profile
4218242
Location
HERSHEY, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$323.56

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $323.56 6

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $223.90 2
AbbVie Inc. $56.68 2
Takeda Pharmaceuticals U.S.A., Inc. $26.01 1
VIVUS LLC $16.97 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHELLE STEPHANIE ROSARIO

NPI 1467847640 · CMS profile ID 4218242

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

HERSHEY, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467847640?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHELLE STEPHANIE ROSARIO, NPI 1467847640, CMS profile ID 4218242. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467847640?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MICHELLE STEPHANIE ROSARIO, NPI 1467847640, CMS profile ID 4218242. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467847640?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MICHELLE STEPHANIE ROSARIO, NPI 1467847640, CMS profile ID 4218242, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1467847640?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $323.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $39.6612/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998684821 CMS
E.R. Squibb & Sons, L.L.C. $119.6812/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016383191 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.0112/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055571659 CMS
VIVUS LLC $16.9708/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030254243 CMS
AbbVie Inc. $17.0207/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998684817 CMS
E.R. Squibb & Sons, L.L.C. $104.2204/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016382811 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $471.96 5
PY2020 $327.72 9
PY2022 $494.33 7
PY2023 $323.56 6
PY2024 $2,893.78 10
PY2025 $14,016.62 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $123,818.41 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 12/19/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223289942
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,934.90 12/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223289200
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,750.00 12/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
TAK-279 CD/UC Ph2 OLE No dispute reported 06/30/2026 1223289202
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,000.00 12/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
TAK-279 CD/UC Ph2 OLE No dispute reported 06/30/2026 1223289204
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,556.69 11/25/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223288769
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 11/25/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223288771
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $319.95 10/03/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223286265
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,530.93 07/10/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223282512
Principal investigator 1 PFIZER INC. $100.00 06/05/2025 Non-covered Recipient Entity
The University of South Florida Board of Trustees
A MULTICENTER PROSPECTIVE NONINTERVENTIONAL STUDY OF REALWORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS ENDEAVOURUC No dispute reported 06/30/2026 1228775133
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $264.60 05/28/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223280382
Principal investigator 1 Eli Lilly and Company $100.65 05/27/2025 Non-covered Recipient Entity
UNIV OF SOUTH FLORIDA RSRCH FOUNDATION
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187891430
Principal investigator 1 PFIZER INC. $8,370.00 05/22/2025 Non-covered Recipient Entity
The University of South Florida Board of Trustees
A MULTICENTER PROSPECTIVE NONINTERVENTIONAL STUDY OF REALWORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS ENDEAVOURUC No dispute reported 06/30/2026 1228778332
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,721.25 04/01/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223277189
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,835.44 03/25/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223277011
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,005.00 03/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223276885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 03/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223276887
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,000.00 03/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223276889
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 03/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223276891
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,255.00 03/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223275927
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 03/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223275929
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,750.00 03/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223275931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,000.00 03/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223275933
Principal investigator 1 Eli Lilly and Company $13,524.00 01/17/2025 Non-covered Recipient Entity
UNIV OF SOUTH FLORIDA RSRCH FOUNDATION
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187892456